

2018 年度

学会発表(国内学会)

2018.08 第3回日本がんサポーターティブケア学会学術集会

1. Role of patient reported outcome (PRO) in supportive/palliative care trial?
中島貴子

2018.10 第56回日本癌治療学会学術集会

1. 高齢がん患者の薬物療法における最適なマネージメントを目指して
中島貴子, 土井綾子, 堀江良樹

2018.11 日本消化器病学会北陸支部教育講演会

1. 大腸癌化学療法～Basic and New～
中島貴子

2019.01 第24回日本緩和医療学会学術集会

1. 緩和ケアを希望する患者の臨床的特徴
楢野宣久, 平川麻美, 藤本晴美, 沼里貞子, 古茶大樹, 月川 賢

2019.02 第91回日本胃癌学会総会

1. Randomized phase II/III study of FL vs. FLTAX in gastric cancer with severe peritoneal metastasis(JCOG1108/WJOG7312G)
Hiroki Hara, Takako Eguchi Nakajima, Kensei Yamaguchi, Narikazu Boku, Ichinosuke Hyodo, Junki Mizusawa, Tomohiro Nishina, Takeshi Sakamoto, Kohei Shitara, Katsunori Shinozaki, Hiroshi Katayama, Shinichiro Nakamura
2. 最新の胃癌治療戦略～IOによる変革
中島貴子
3. 胃癌における免疫療法 最新のエビデンスを実臨床で活かすには
中島貴子
4. 患者アドボカシーワークショップ
中島貴子
5. 胃がん治療戦略～アンメットメディカルニーズにどう対応するか～
中島貴子
6. Perspectives of postoperative chemotherapy for gastric cancer: From Asian point of view.
Takako Eguchi Nakajima
7. Perspectives of postoperative chemotherapy for gastric cancer: From Asian point of view.
Takako Eguchi Nakajima

2018.04 American Association for Cancer Research

1. Phase I study of the anti-heparin binding-EGF antibody U3-1565 with cetuximab in patients with cetuximab- or panitumumab-resistant metastatic colorectal cancer

Takako Eguchi Nakajima, Narikazu Boku, Hiroyuki Arai, Takuro Mizukami, Yoshiki Horie, Naoki Izawa, Mami Hirakawa, Takashi Ogura, Takashi Tsuda, Yu Sunakawa.

2018.06 American Society Clinical Oncology

1. Initial therapy with FOLFOXIRI plus bevacizumab (bev) for RAS mutant metastatic colorectal cancer (mCRC) and gene mutations in circulating tumor DNA (ctDNA) as a predictive marker for the efficacy: JACCRO CC-11.

Yu Sunakawa, Hironaga Satake, Joshua L. Usher, Yolanda S Jaimes, Yuji Miyamoto, Masato Nakamura, Hiroshi Nakayama, Nobuhiro Sugano, Akinori Takagane, Masahiro Gotoh, Takanori Watanabe, Kiyoshi Ishigure, Chihiro Tanaka, Masahiro Takeuchi, Masashi Fujii, KATHLEEN DANENBERG, Heinz-Josef Lenz, Takashi Sekikawa, Wataru Ichikawa.a

2018.10 European Society for Medical Oncology

1. Antibiotics may enhance the efficacy of gemcitabine treatment for advanced pancreatic cancer
Y. Sunakawa, H. Arai, N. Izawa, T. Mizukami, Y. Horie, A. Doi, M. Hirakawa, T. Ogura, T. Tsuda, T.E. Nakajima.
2. Gene mutation status in circulating tumor DNA (ctDNA) and 1st-line FOLFOXIRI plus bevacizumab (bev) in metastatic colorectal cancer (mCRC) harboring RAS mutation
Y. Sunakawa, J. Usher, H. Satake, Y. Jaimes, Y. Miyamoto, M. Nakamura, M. Kataoka, M. Shiozawa, A. Takagane, T. Terazawa, T. Watanabe, K. Ishigure, C. Tanaka, T. Sekikawa, M. Takeuchi, M. Fujii, K. Danenberg, P.V. Danenberg, H.J. Lenz, W. Ichikawa.
3. A biomarker study to validate predictors for clinical outcome of cetuximab based chemotherapy in first-line metastatic colorectal cancer (mCRC) patients: JACCRO CC-05/06AR and FIRE-3
Y. Sunakawa, S. Stintzing, S. Cao, J. Luecke, D. Thompson, M. Moran, S.H. Astrow, J. Hsiang, C. Stephens, W. Zhang, A. Tsuji, T. Takahashi, T. Denda, K. Shimada, M. Kochi, M. Takeuchi, M. Fujii, W. Ichikawa, V. Heinemann, H.J. Lenz.
4. Dynamic change of immune-related gene expression status during chemoradiotherapy in locally advanced esophageal cancer
T. Mizukami, Y. Sunakawa, H. Arai, M. Chosokabe, A. Doi, Y. Horie, M. Hirakawa, O. Saji, S. Naruki, N. Izawa, T. Ogura, T. Tsuda, T. Enomoto, S. Mikami, T. Fujino, T. Otsubo, T. Nakajima.

2018.11 ESMO-ASIA

1. Case presentation Metastatic oeso-gastric cancer WHY we need an Asian guideline for oeso-gastric cancer?
Takako Eguchi Nakajima.

2018.12 ESMO-Immuno

1. A translational study to discover novel host-related immune-biomarkers for nivolumab (Nivo) in advanced gastric cancer (GC): JACCRO GC-08 (DELIVER trial)
Y. Sunakawa, K. Muro, T.E. Nakajima, H. Kawakami, E. Inoue, R. Matoba, Y. Sato, W. Ichikawa, M. Fujii.

2019.01 ASCO-GI

1. Prospective evaluation of a developed S-1 dosage formula based on renal function.
Takuro Mizukami, Masashi Takeuchi, Chiyo K. Imamura, Eisuke Booka, HIROYA TAKEUCHI, Takeshi Kawakami, Taro Funakoshi, Kazushige Wakuda, Yu Aoki, Yasuo Hamamoto, Minoru Kitago, Hirofumi Kawakubo, Narikazu Boku, Yusuke Tanigawara, Yuko Kitagawa.
2. Identification of site-specific genome alterations in metastatic colorectal cancer: Sub-study 003 of the SCRUM-Japan GI-SCREEN
Takuro Mizukami, Masaki Takahashi, Yu Sunakawa, Satoshi Yuki, Yoshinori Kagawa, Atsuo Takashima, Kyoko Kato, Hiroki Hara, Tadamichi Denda, Toshikazu Moriwaki, Manabu Shiozawa, Eiji Oki, Taroh Satoh, Hisato Kawakami, Taito Esaki, Tomohiro Nishina, Wataru Okamoto, Takayuki Yoshino, Takako Eguchi Nakajima.
3. Randomized phase II/III study of 5-fluorouracil /l-leucovorin vs. 5-fluorouracil /l-leucovorin plus paclitaxel in gastric cancer with severe peritoneal metastasis (JCOG1108/WJOG7312G). American Society of Clinical Oncology, Gastrointestinal Cancer Symposium 2019 poster presentation
Kensei Yamaguchi, Takako Eguchi Nakajima, Narikazu Boku, Ichinosuke Hyodo, Junki Mizusawa, Hiroki Hara, Tomohiro Nishina, Takeshi Sakamoto, Kohei Shitara, Katsunori Shinozaki, Hiroshi Katayama, Shinichiro Nakamura.
4. CEA response at 4 wks as an early predictor for outcomes in patients (pts) with metastatic colorectal cancer (mCRC) treated with 1st-line cetuximab-based chemotherapy: a STEP-analysis in the JACCRO CC-05/06 trials.
Yu Sunakawa, Xuemin Fang, Masahito Kotaka, Hiroaki Tanioka, Akinori Takagane, Satoshi Tani, Tatsuro Yamaguchi, Takanori Watanabe, Toshiki Masuishi, Masahiro Tsuda, Tatsuya Okuno, Takao Tamura, Kaoru Furushima, Hidekazu Kuramochi, Junichi Koike, Yutaka Yonemura, Hisateru Yasui, Masahiro Takeuchi, Masashi Fujii, Wataru Ichikawa.

論文業績(和文)

《原著・総説・解説》

1. 抗体薬 ラムシルマブ、アフリベルセプト
 - 腫瘍内科, 21(6): 646-653, 2018.
 - 伊澤直樹, 中島貴子
2. 胃癌化学療法におけるチーム医療の取り組み
 - 日本消化器病学会雑誌, 115(6): 521-528, 2018.
 - 伊澤直樹, 中島貴子
3. ASCOレポート、HIPEC・WJOG7112G(beyond Tmab)
 - 消化器病広場, 2018.
 - 伊澤直樹

4. nab-PTX/RAM

- 消化器癌化学療法レジメンハンドブック, 2018.
- 伊澤直樹

5. がん化学療法の薬はや調べノート 2019・2020 年版

- がんナーシング 2019 年別冊, 2018.
- 新井裕之, 伊澤直樹, 小倉孝氏, 中島貴子

6. DNA ミスマッチ修復欠損または MSI-high と免疫チェックポイント阻害薬効果の相関

- がん分子標的治療, 16(2): 94-97, 2018.
- 砂川 優

7. クリニカルシーケンスを基にした分子標的治療の展開

- 病理と臨床, 36(7): 676-680, 2018.
- 水上拓郎, 砂川優, 中島貴子

8. Pan-Asian adapted ESMO consensus guideline の概要

- 腫瘍内科, 22(1): 2-8, 2018.
- 水上拓郎, 中島貴子

9. 大腸がんに対する臨床開発と方向性

- 腫瘍内科, 22(1): 45-53, 2018.
- 砂川 優

10. 胃癌・RAM(単剤, RAM+PTX)

- エビデンスに基づいた癌化学療法ハンドブック 2018, 318-320, 2018.
- 新井裕之, 中島貴子

11. 薬物療法によってフレイル状態に陥りやすい高齢がん患者への対応

- 臨床腫瘍プラクティス, 14(4): 249-254, 2018.
- 土井綾子, 堀江良樹, 中島貴子

12. 疾患別に学ぼう！ 9 消化器癌

- ヘルスケアプロバイダのためのがん生殖医療, 2018.
- 小倉孝氏

13. 消化器外科専門医の心得

- 消化器外科専門医の心得, 2018.
- 伊澤直樹

14. 消化器(口内炎、食欲不振、悪心嘔吐、下痢脱水)

- 消化器がん化学療法副作用マネジメント, 2018.
- 土井綾子, 堀江良樹, 中島貴子

15. GI Cancer Selected Papers

- GI Cancer Cutting Edge, 2018.
- 伊澤直樹

16. 分子標的薬の最適な治療シーケンス:大腸がん

- がん分子標的治療, 2018.
- 伊澤直樹

17. 後方ライン治療におけるICのポイント

- 大腸癌に対するレゴラフェニブ治療, 80-84, 2019.
- 新井裕之

18. dMMR/MSI-H 大腸がんの治療

- 癌と化学療法, 45(11): 1602-1607, 2018.
- 砂川 優

19. 肝機能障害への対応

- がん免疫療法, 2018.
- 新井裕之

20. 抗 EGFR 抗体薬使用後の薬剤耐性クローンの指数関数的減少:抗 EGFR 抗体薬の re-challenge への影響

- 消化器病広場, 2019.
- 伊澤直樹

21. 腫瘍内科医に必要な緩和医療のポイント

- 臨床腫瘍プラクティス, 2019.
- 土井綾子

文業績(英文)

《原著・総説》

1. Prognostic impact of FOXF1 polymorphisms in gastric cancer patients.

- Pharmacogenomics J. 18(2): 262-269, 2018.
- Matsusaka S, Wu AH, Cao S, Hanna DL, Chin K, Yang D, Zhang W, Ning Y, Stintzing S, Sebio A, Sunakawa Y, Stremitzer S, Yamauchi S, Okazaki S, Berger MD, Parekh A, Miyamoto Y, Mizunuma N, Lenz HJ.

2. A phase II trial of 1st-line modified-FOLFOXIRI plus bevacizumab treatment for metastatic colorectal cancer harboring RAS mutation: JACCRO CC-11.

 - Oncotarget. 9: 18811–18820, 2018.
 - Hironaga Satake, Yu Sunakawa, Yuji Miyamoto, Masato Nakamura, Hiroshi Nakayama, Manabu Shiozawa, Akitaka Makiyama, Kazuma Kobayashi, Yutaro Kubota, Misuzu Mori, Masahito Kotaka, Akinori Takagane, Masahiro Gotoh, Masahiro Takeuchi, Masashi Fujii, Wararu Ichikawa and Takashi Sekikawa.
3. Reply to L. Celio et al.

 - LJ Clin Oncol. 78, 2018.
 - Yuka Ito, Takashi Tsuda, Kentaro Sakamaki, Takako Eguchi Nakajima.o
4. Esophagogastric varices were diagnosed in a non-cirrhotic liver case during long-term follow-up after oxaliplatin-based chemotherapy.

 - Clinical Journal of Gastroenterology. 11(6): 487–492, 2018.
 - Ryuta Shigefuku, Tsunamasa Watanabe, Takuro Mizukami, Kotaro Matsunaga, Nobuhiro Hattori, Takuya Ehira, Tatsuya Suzuki, Hiroyasu Nakano, Yoshinori Sato, Yasumasa Matsuo, Kazunari Nakahara, Hiroki Ikeda, Nobuyuki Matsumoto, Takashi Tsuda, Masafumi Katayama, Satoshi Koizumi, Chiaki Okuse, Michihiro Suzuki, Takehito Otsubo, Takako Eguchi Nakajima, Hiroshi Yasuda, Fumio Itoh.
5. Rationale and design of the TRUSTY study: a randomised, multicentre, open-label phase II/III study of trifluridine/tipiracil plus bevacizumab versus irinotecan, fluoropyrimidine plus bevacizumab as second-line treatment in patients with metastatic colorectal cancer progressive during or following first-line oxaliplatin-based chemotherapy.

 - ESMO Open. 3(5), 2018.
 - Takayuki Yoshino, Eiji Oki, Hiroaki Nozawa, Takako Eguchi-Nakajima, Hiroya Taniguchi, Satoshi Morita, Naruhito Takenaka, Daisuke Ozawa, Kuniaki Shirao.
6. Immune-related genes to dominate neutrophil-lymphocyte ratio (NLR) associated with survival of cetuximab treatment in metastatic colorectal cancer.

 - Clinical Colorectal Cancer, 2018.
 - Yu Sunakawa, Dongyun Yang, Shu Cao, Wu Zhang, Miriana Moran, Stephanie H. Astrow, Jack Hsiang, Craig Stephens, Akihito Tsuji, Takehiro Takahashi, Hiroaki Tanioka, Yuji Negoro, Akinori Takagane, Satoshi Tani, Tatsuro Yamaguchi, Tetsuya Eto, Masashi Fujii, Wataru Ichikawa, Heinz-Josef Lenz.
7. A subanalysis of Japanese patients in a randomized, double-blind, placebo-controlled, phase 3 trial of nivolumab for patients with advanced gastric or gastro-esophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens (ONO-4538-12, ATTRACTION-2).

 - Gastric Cancer, 2018.
 - Kato K, Satoh T, Muro K, Yoshikawa T, Tamura T, Hamamoto Y, Chin K, Minashi K, Tsuda M, Yamaguchi K, Machida N, Esaki T, Goto M, Komatsu Y, Nakajima TE, Sugimoto N, Yoshida K, Oki E, Nishina T, Tsuji A, Fujii H, Kunieda K, Saitoh S, Omuro Y, Azuma M, Iwamoto Y, Taku K, Fushida S, Chen LT, Kang YK, Boku N.

8. Tumor sidedness and enriched gene groups for efficacy of first-line cetuximab treatment in metastatic colorectal cancer.

 - Molecular Cancer Therapeutics, 2018.
 - Sunakawa Y, Mogushi K, Lenz HJ, Zhang W, Tsuji A, Takahashi T, Denda T, Shimada K, Kochi M, Nakamura M, Kotaka M, Segawa Y, Tanioka H, Negoro Y, Moran M, Astrow SH, Hsiang J, Stephens C, Fujii M, Ichikawa W.

9. Pan-Asian adapted ESMO Clinical Practice Guidelines for the management of patients with metastatic oesophageal cancer: a JSMO-ESMO initiative endorsed by CSCO, KSMO, MOS, SSO and TOS. *Annals of Oncology* 30: 34-43, 2019 doi:10.1093/annonc/mdy498.

 - *Annals of Oncology*, 30(1): 34-43, 2019.
 - K. Muro, F. Lordick, T. Tsushima, G. Pentheroudakis, E. Baba, Z. Lu, B. C. Cho, I. M. Nor, M. Ng, L.-T. Chen, K. Kato, J. Li, M.-H. Ryu, W. I. Wan Zamaniah, W.-P. Yong, K.-H. Yeh, T. E. Nakajima, K. Shitara, H. Kawakami, Y. Narita, T. Yoshino, E. Van Cutsem, E. Martinelli, E. C. Smyth, D. Arnold, H. Minami, J. Tabernero & J.-Y. Douillard.

10. Guidelines for the management of patients with metastatic gastric cancer: a JSMO-ESMO initiative endorsed by CSCO, KSMO, MOS, SSO and TOS.

 - *Annals of Oncology*, 30(1): 19-33, 2019.
 - K. Muro, E. Van Cutsem, Y. Narita, G. Pentheroudakis, E. Baba, J. Li, M.-H. Ryu, W. I. Wan Zamaniah, W.-P. Yong, K.-H. Yeh, K. Kato, Z. Lu, B. C. Cho, I. M. Nor, M. Ng, L.-T. Chen, T. E. Nakajima, K. Shitara, H. Kawakami, T. Tsushima, T. Yoshino, F. Lordick, E. Martinelli, E. C. Smyth, D. Arnold, H. Minami, J. Tabernero & J.-Y. Douillard.

11. Phase II trial of aflibercept with FOLFIRI as a second-line treatment for Japanese patients with metastatic colorectal cancer.

 - *BMC Cancer*,97(2):94-101, 2019.
 - Tadamichi Denda, Daisuke Sakai, Tetsuya Hamaguchi, Naotoshi Sugimoto, Takashi Ura, Kentaro Yamazaki, Hirofumi Fujii, Takeshi Kajiwara, Takako Eguchi Nakajima, Shin Takahashi, Satoshi Otsu, Yoshito Komatsu, Fumio Nagashima, Toshikazu Moriwaki, Taito Esaki, Takeo Sato, Michio Itabashi, Eiji Oki, Toru Sasaki, Yoshinori Sunaga, Samira Ziti-Ljajic, Claire Brillac, Takayuki Yoshino.

12. A randomized phase II study of nutritional and exercise treatment for elderly patients with advanced non-small cell lung or pancreatic cancer: the NEXTAC-TWO study protocol.

 - *Cancer Science*, 110(3): 1032-1043, 2019.
 - Miura S, Naito T, Mitsunaga S, Omae K, Mori K, Inano T, Yamaguchi T, Tatematsu N, Okayama T, Morikawa A, Mouri T, Tanaka H, Kimura M, Imai H, Mizukami T, Imoto A, Kondoh C, Shiotsu S, Okuyama H, Ueno M, Takahashi T, Tsuji T, Aragane H, Inui A, Higashiguchi T, Takayama K.